A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

Abstract Background Biliary tract cancers (BTCs) are rare and lethal cancers, with a 5-year survival inferior to 20%(1–3). The only potential curative treatment is surgical resection. However, despite complex surgical procedures that have a remarkable risk of postoperative morbidity and mortality, t...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Monica Niger, Federico Nichetti, Lorenzo Fornaro, Chiara Pircher, Federica Morano, Federica Palermo, Lorenza Rimassa, Tiziana Pressiani, Rossana Berardi, Andrea Casadei Gardini, Elisa Sperti, Lisa Salvatore, Davide Melisi, Francesca Bergamo, Salvatore Siena, Stefania Mosconi, Raffaella Longarini, Giuseppina Arcangeli, Salvatore Corallo, Laura Delliponti, Stefano Tamberi, Elena Fea, Giovanni Brandi, Ilario Giovanni Rapposelli, Massimiliano Salati, Paolo Baili, Rosalba Miceli, Silva Ljevar, Ilaria Cavallo, Elisa Sottotetti, Antonia Martinetti, Michele Droz Dit Busset, Carlo Sposito, Maria Di Bartolomeo, Filippo Pietrantonio, Filippo de Braud, Vincenzo Mazzaferro
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2024-04-01
סדרה:	BMC Cancer
נושאים:	Biliary tract cancers Cholangiocarcinoma Neoadjuvant chemotherapy Cisplatin gemcitabine nabpaclitaxel
גישה מקוונת:	https://doi.org/10.1186/s12885-024-12225-6
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!